Cyril Abdeddaim

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology · 2020 · 357 citations · Full text

Medicine, Oncology, Pharmacology +16

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Thierry André, Dominique Berton, Giuseppe Curigliano et al. · JAMA Network Open · 2023 · 120 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Thierry André, Dominique Berton, Giuseppe Curigliano et al. · Journal of Clinical Oncology · 2021 · 98 citations

Pharmacy, Oncology, Pharmacology +17

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Pierre‐Etienne Heudel, Jean‐Sébastien Frenel, Cécile Dalban et al. · JAMA Oncology · 2022 · 79 citations · Full text

Medicine, Oncology, Pharmacology +16